Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Do you have a question on gene-disease associations that are not covered on this page? Or would you like to know more about the Euretos AI Platform? Please fill in your contact details and we will reach out to you!

Euretos presenting in the Scale-Up track at the Innovation for Health conference

Monday 03 February 2020

Arie Baak, co-founder of Euretos, will be presenting at the Innovation for Health conference. This year’s event will take place in Rotterdam and Euretos will present as part of the Scale-Up track, February 13th at 11:30 in the Hudag Room.


In the Scale-Up track selects a limited number of selected companies that are growing fast are invited to present their capabilities and connect with connect with potential partners, future customers, leading investors and other stakeholders to further realise their ambitions.

Euretos will present on how it’s applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.


Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence. 


State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.


These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.


Please contact us at the Euretos website if you would like to meet during the event!